Total GLP-1 ELISA

(10-1278-01)

Kit format: 1 x 96 wells

Measurement range: 0.9 - 940 pmol/L (2.8 - 2940 pg/mL)

100% specificity to the predominating isoform, GLP-1 (9-36) amide

High sensitivity

Validated according to CLSI/FDA/EMA

Controls available: 10-1287-01

TALK TO A PERSON

Description

Mercodia Total GLP-1 ELISA

The Mercodia Total GLP-1 ELISA provides a chemiluminescent method for the quantitative determination of amidated glucagon-like-peptide-1 (GLP-1) in human plasma and serum samples. The assay has been validated according to CLSI, FDA, and EMA guidelines.

GLP-1, is one of the major incretin hormones produced in the intestinal L-cells. It is secreted as the active forms (7-37)/(7-36) amide but is rapidly cleaved by the enzyme DPP4 forming the metabolites GLP-1 (9-37)/(9-36) amide. Although the two active forms have shown equal biological potency, the majority of circulating GLP-1 in humans is found in the amidated form.

Mercodia GLP-1 (9-36) Amide Control – Low, Medium, High (10-1287-01) is a three-level control for the Mercodia Total GLP-1 ELISA.

Test characteristics

Species

Human

Sample types

Serum and EDTA plasma

Sample volume

25 µL

Assay range

0.9 - 940 pmol/L (2.8 - 2940 pg/mL)

Detection limit

≤0.65 pmol/L

Incubation

2h + 15 min

Detection method

Chemiluminescence

specificity

The following cross-reactions have been tested:

GLP-1 (1-36) amide

88%

GLP-1 (7-36) amide

93%

GLP-1 (9-36) amide

100%

GLP-1 (1-37)

Not detected

GLP-1 (7-37)

Not detected

Glucagon

Not detected

GIP

Not detected

GLP-2

Not detected

Oxyntomodulin

Not detected

Glicentin

Not detected

Miniglucagon

Not detected

MPGF

Not detected

Liraglutide

Not detected

Exenatide

Not detected

Lixisenatide

Not detected

Dulaglutide

0.07%

directions for use Certificate of Analysis Safety Data Sheet

directions for use

LOT. NO.	DOCUMENT
35965	DfU - 10-1278-01 v. 6.0
34076	DfU - 10-1278-01 v. 6.0
35491	DfU - 10-1278-01 v. 6.0
35652	DfU - 10-1278-01 v. 6.0

Certificate of Analysis

LOT. NO.	DOCUMENT
35965	CoA - 10-1278-01
35652	CoA - 10-1278-01
35491	CoA - 10-1278-01
34076	CoA - 10-1278-01

Safety Data Sheet

DOCUMENT
SDS - 10-1278-01

For other languages and previous versions: Technical Library

technical notes

For technical notes specific to Mercodia Total GLP-1 ELISA see:
TN34-0154 Sample collection and handling for Mercodia Total GLP-1 ELISA (10-1278-01)

For other technical notes see our Technical Library

references

Stinson, S. E. et al. (2021). Fasting plasma GLP-1 associates with overweight/obesity and cardiometabolic risk factors in children and adolescents. The Journal of Clinical Endocrinology & Metabolism. Read more >

Jepsen, S. L. et al. (2021). Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut-and GLP-1R-dependent manner. Read more >

Vestergaard, E. T. et al. (2021). Acute ketosis inhibits appetite and decreases plasma concentrations of acyl ghrelin in healthy young men. Diabetes, Obesity and Metabolism, 23(8), 1834–1842. Read more >

Grevengoed, T. J. et al. (2021). An abundant biliary fatty acid metabolite derived from dietary omega-3 polyunsaturated fatty acids regulates triglycerides. Journal of Clinical Investigation. Read more >

Docherty, K. F. et al. (2021). The Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients with Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. Circulation, CIRCULATIONAHA.121.054892 Read more >

Meessen, E. C. E. et al. (2021). Parenteral nutrition impairs plasma bile acid and gut hormone responses to mixed meal testing in lean healthy men. Clinical Nutrition, 40(3). Read more >

Rega-Kaun, G. et al. (2020). Roux-en-Y-Bariatric Surgery Reduces Markers of Metabolic Syndrome in Morbidly Obese Patients. Obesity Surgery, 30(2), 391–400 Read more >

Kaya, D. et al. (2019). TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats. Cells, 8(10), 1153. Read more >

Seelig, E. et al. (2019). Exercise and the dipeptidyl‐peptidase IV inhibitor sitagliptin do not improve beta‐cell function and glucose homeostasis in long‐lasting type 1 diabetes—A randomised open‐label study. Endocrinology, Diabetes & Metabolism, e00075. Read more >

Grevengoed, T. J. et al. (2019). N-acyl taurines are endogenous lipid messengers that improve glucose homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 116(49), 24770–24778. Read more >

Roberts, G. P. et al. (2018). Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 14(5), 562–568. Read more >